Emil Nasyrov

Dr. Emil Nasyrov

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2024 in Ocular Immunology and Inflammation
Verified
Journal Article
Open access
ENEmil Nasyrov
Emil Nasyrov
CSClara Seppelfricke
Clara Seppelfricke
DDDeshka Doycheva
Deshka Doycheva
CGCaroline J. Gassel
Caroline J. Gassel
DMDavid A. Merle
David A. Merle
BVBogomil Voykov
Bogomil Voykov
PurposeTo investigate the efficacy and safety of the Preserflo MicroShunt (PMS) in treating glaucoma secondary to different uveitic glaucoma (UG) types in a European population.MethodsThis study evaluated consecutive eyes with UG that received the PMS. The primary outcome measure was 12-month surgical success (>= 20% IOP reduction, target IOP of 6-21 mmHg). Complete success was considered without IOP-lowering medication or additional surgery other than needling. Qualified success A was considered regardless of medication use, and qualified success B regardless of medication and/or incisional bleb revision. The secondary outcome measures included revision and complication rates.ResultsTwenty-five eyes (viral group: 10 with Fuchs uveitis syndrome and six with herpetic uveitis; juvenile idiopathic arthritis (JIA) group: nine with JIA-related uveitis) were included. The 12-month complete success rate was significantly higher in the viral group than in the JIA group (69% vs 11%; p = 0.0059, log-rank test). The qualified success rates in the viral and JIA groups were 75% and 22% for category A (p = 0.029) and 94% and 56% for category B (p = 0.0237), respectively. Among the viral and JIA groups, 13% and 11% required medication, respectively. Incisional bleb revisions were conducted within 12 months in 25% and 78%, respectively (p = 0.0131, log-rank test). Complications were self-limiting, with no uveitic activity observed.ConclusionThe PMS is safe and effective for glaucoma secondary to viral anterior uveitis. Conversely, it is moderately effective in eyes with JIA-related UG, with a high probability of bleb fibrosis development.

21 June 2024 in BMC Ophthalmology
Verified
Journal Article
Open access
PDF file
ENEmil Nasyrov
Emil Nasyrov
CGCaroline J. Gassel
Caroline J. Gassel
DMDavid A. Merle
David A. Merle
JNJonas Neubauer
Jonas Neubauer
BVBogomil Voykov
Bogomil Voykov
Background: Minimally invasive bleb surgery using the XEN-45 gel stent has not been established for the treatment of normal-tension glaucoma (NTG). The main objective of this study was to evaluate the long-term treatment efficacy and safety of XEN-45 in eyes with uncontrolled NTG. Methods: A retrospective analysis of patients with NTG who underwent XEN-45 gel stent implantation at university hospital Tuebingen between 2016 and 2021. The primary outcome measure was surgical success after three years defined as lowering of intraocular pressure (IOP) of ≥ 20%, with target IOP between 6 and 15 mmHg. Success was complete without and qualified irrespective of topical antiglaucoma medication use. The need for further glaucoma surgery, except for needling, was regarded as a failure. The secondary outcome measures included changes in mean IOP, number of antiglaucoma medications, and needling and complication rates. Results: Twenty-eight eyes from 23 patients were included in the final analysis. Complete and qualified success rates were 56.5% and 75% after three years, respectively. Mean postoperative IOP ± standard deviation decreased significantly after three years from 19.3 ± 2.0 mmHg at baseline to 13.7 ± 4.2 mmHg (n = 22; p < 0.0001). The median number of antiglaucoma medications decreased from 2 (range 0–4) to 0 after three years (range 0–3; p < 0.0001). Sixteen eyes (57%) required a median of 1 (range 1–3) needling procedures. One eye required further glaucoma surgery. No sight-threatening complications were observed. Conclusion: The XEN-45 stent is effective and safe for the long-term treatment of NTG. However, needling was frequently required to improve outcomes.

1 August 2023 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
Bogomil VoykovBogomil Voykov
Bogomil Voykov
ENEmil Nasyrov
Emil Nasyrov
JNJonas Neubauer
Jonas Neubauer
CGCaroline J Gassel
Caroline J Gassel
Purpose: The XEN gel stent was developed to reduce the risks of filtration surgery by standardizing the outflow of aqueous humor into the subconjunctival space. Recently, a modified version of the XEN63 gel stent was introduced. The goal of this study was to assess its efficacy and safety. Methods: This is a prospective, nonrandomized, observational, consecutive case series study at a single tertiary centre. Patients with open-angle glaucoma with above target intraocular pressure (IOP) despite maximal tolerated medication were included. The primary outcome was a change of median IOP. Secondary outcomes included a change in the number of medications, complete success, needling and complication rates. Success was defined as a lowering of IOP > 20% from baseline and IOP ≤ 14 mmHg. Complete success indicated that the target IOP was reached without medications. Results: Six patients were included. The median IOP decreased from 35.5 mmHg (25.0– 40.0 mmHg) at baseline to 11.5 mmHg (4.0– 15.0 mmHg, p = 0.03), and median IOP-lowering medication was reduced from 4.0 (3.0– 4.0) at baseline to 0 (0– 1.0, p = 0.03) after two years. Five patients (83.0%) had a complete success after two years. Two patients (33.0%) required a needling procedure. Three patients (50.0%) required an intervention due to symptomatic hypotony within the first three weeks postoperatively. Hypotony resolved completely or was asymptomatic after three months. Conclusion: Our study demonstrated a statistically significant reduction in both IOP and number of IOP-lowering medications. Complications were well manageable and had no long-term sequelae.

21 October 2025 in Acta Ophthalmologica
Verified
Journal Article
Open access
ENEmil Nasyrov
Emil Nasyrov
IKIsabel Kommerell
Isabel Kommerell
ISIsabell Schleicher
Isabell Schleicher
DMDavid Merle
David Merle
CWCaroline J. Wenzel
Caroline J. Wenzel
Bogomil VoykovBogomil Voykov
Bogomil Voykov
Purpose: To evaluate the incidence, outcomes, and risk factors of numerical hypotony (NH) and choroidal effusion (CE) following standalone PRESERFLO MicroShunt (PMS) implantation. Methods: Primary open‐angle glaucoma (POAG) and pseudoexfoliative glaucoma (PXG) patients with uni‐ or bilateral surgery at a tertiary university hospital were retrospectively evaluated. Kaplan–Meier estimates of first‐operated eyes were used to analyse the cumulative incidence of NH (intraocular pressure [IOP] of <6 mmHg), CE, and CE requiring intervention. Risk factor analyses were performed using generalised linear mixed models on the patient level, including bilateral cases. Results: In total, 370 patients (235 POAG and 135 PXG) and 435 eyes (288 and 147) were included. The PXG group had a significantly higher incidence of NH (83.7% vs. 69.4%) and CE (34.6% vs. 20.6%). Interventions for CE were required significantly more in PXG patients (20.7% vs. 7.4%). The median CE duration was significantly longer in the PXG group (14 days vs. 7 days). The following risk factors were identified: PXG (development of NH, CE, and CE requiring intervention); spherical hyperopic refractive error (CE and CE requiring intervention); male sex and higher age (CE); number of preoperative medications (CE requiring intervention), lower preoperative IOP (NH), and higher postoperative IOP drop (CE). The 6‐month visual outcomes were not influenced by the hypotony criteria, but significantly more eyes treated for CE required subsequent bleb revisions. Conclusion: PXG and hyperopic eyes were at risk for developing postoperative CE requiring intervention. They should be monitored more closely and would benefit from primary intraluminal stenting.

Verified
Journal Article
Open access
PDF file
ENEmil Nasyrov
Emil Nasyrov
DMDavid Merle
David Merle
CGCaroline J. Gassel
Caroline J. Gassel
DWDaniel A. Wenzel
Daniel A. Wenzel
Bogomil VoykovBogomil Voykov
Bogomil Voykov
Objectives: To investigate whether phakia affects the outcome of XEN-45 gel stent implantation in the treatment of pseudoexfoliative glaucoma (PXG). Methods: A retrospective, comparative cohort study of 30 phakic and 55 pseudophakic PXG patients who received the XEN-45 gel stent at a tertiary centre. The primary outcome measure was two-year success defined as a ≥20% lowering of intraocular pressure (IOP) and a target IOP of 6–21 mmHg. Success was complete without and qualified irrespective of antiglaucoma medication use. Further glaucoma surgery other than needling was regarded as a failure. The secondary outcome measures included changes in IOP, revision and complication rates. Results: The complete two-year success rates were 70% and 59% in the phakic and pseudophakic groups, respectively (p = 0.75, log-rank test), and the qualified rates were 80% and 72%, respectively (p = 0.89). The median IOP reduction from baseline was 54% in phakic, and 46% in pseudophakic eyes. While needling rates were similar, the incidence of early incisional bleb revisions was significantly higher in the phakic eyes (13% vs. 0% within 3 months; p = 0.0098, chi-square). Increasing after a year, significantly more pseudophakic eyes failed due to secondary glaucoma surgery (16% vs. 0%; p = 0.0191). Conclusions: The XEN-45 gel stent offers equally effective IOP control for both phakic and pseudophakic patients. However, the onset of bleb revisions and the necessity for secondary glaucoma surgery differed significantly between the groups.

1 November 2025 in RETINAL Cases & Brief Reports
Verified
Journal Article
Open access
DMDavid Merle
David Merle
LWLasse Wolfram
Lasse Wolfram
ENEmil Nasyrov
Emil Nasyrov
MRMilda Reith
Milda Reith
MKMartin Kowalski
Martin Kowalski
LKLaura Kühlewein
Laura Kühlewein
Purpose: To describe the clinical course and treatment response of a case of acute zonal occult outer retinopathy. Methods: This is an observational case report. The examinations included ophthalmic examination, longitudinal multimodal imaging, visual field testing, electrophysiologic recordings, serologic analyses, and whole genome sequencing. Results: In this report, the authors present the case of an otherwise healthy 33-year-old woman with bilateral acute zonal occult outer retinopathy manifestation. Other possible causes of the observed retinal lesions were ruled out by extensive diagnostic workup. Treatment with oral prednisolone therapy led to temporal disease control but progression was observed after prednisolone discontinuation. A tapered oral prednisolone therapy in combination with adalimumab initiation prevented further progression for at least 21 months. Conclusion: Diagnosis of acute zonal occult outer retinopathy is frequently complicated by the unspecific symptoms of the disease and significant number of differential diagnoses. Complete diagnostic workup is important to rule out other etiologies. Owing to the lack of randomized controlled trials, therapeutic decisions obligatorily rely on empiric treatment decisions in combination with frequent follow-up examinations.